Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Condition: Head and Neck Cancer Interventions: Drug: Xevinapant; Drug: Cisplatin; Radiation: intensity-modulated radiation therapy (IMRT) Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Germany Health | Intensity-Modulated Radiation Therapy | Radiation Therapy | Research | Study